氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究*

doi:10.3969/j.issn.1672-5069.2022.05.005

Abstract

Abstract: Objective The aim of this experiment was to observe the protective effect of oxymatrine (OMT) on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases (NAFLD). Methods 40 SD rats were randomly divided into control, model, OMT –intervened and simvastatin-intervened groups, with 10 rats in each. The NAFLD model was established by high-fat diet feeding. Since 9^th week, the normal saline, OMT or simvastatin was given by gavage, and the management continued to 16^th week. Serum interleukin-1β (IL-1β), IL-6, IL-10 and tumor necrosis factor-α (TNF-α), and liver homogenate superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) levels were detected. Results The body mass and liver mass in OMT-intervened group were(610.3±9.4)g and (11.6±0.7)g, significantly lower than [(631.8±13.9)g and (13.9±0.6)g, respectively, P<0.05] in the model; serum ALT and AST levels were(78.9±7.0)U/L and (120.4±11.3)U/L, significantly lower than [(96.7±11.4)U/L and (183.1±25.9)U/L, respectively, P<0.05] in the model; serum TC, TG and LDL levels were (2.0±0.2)mmo/L, (2.2±0.1)mmo/L and (1.0±0.1)mmo/L, significantly lower than [(2.4±0.2)mmo/L, (2.8±0.2)mmo/L and (1.2±0.2)mmo/L, respectively, P<0.05] in the model group; serum IL-1β, IL-6 and TNF-α levels were (6.4±1.8)pg/ml, (63.7±8.5)pg/ml and (13.9±1.9)pg/ml, significantly lower than [(13.9±8.4)pg/ml, (149.8±12.0)pg/ml and (36.5±2.9)pg/ml, respectively, P<0.05], while serum IL-10 level was (42.3±2.0) pg/ml, significantly higher than [(18.9±1.9)pg/ml, P<0.05] in the model; the liver homogenate SOD and GSH levels were (22.3±2.1)μg/mg and (26.0±2.1)U/mg, significantly higher than [(17.5±1.9)μg/mg and (15.8±1.8)U/mg, respectively, P<0.05] while MDA level was (17.9±2.2)nmol/mg, significantly lower than [(23.8±2.7)nmol/mg, P<0.05] in the model. Conclusion Oxymatrine could protect the liver function of rats with NAFLD and reduce blood lipids levels, which might be related to its anti-inflammatory and anti-oxidative stress effects.

Key words: Non-alcoholic fatty liver diseases, Oxymatrine, Steatosis, Rats

Zeng Ting, Lei Xiangyang, Bai Xiaosu. Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(5): 624-627.

References

[1]Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers. J Hepatol, 2018,68(2):305-315.
[2]Abenavoli L, Greco M, Milic N,et al. Effect of Mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease:A randomized study. Nutrients, 2017,9(8):870.
[3]Shimizu M, Suzuki K, Kato K,et al. Evaluation of the effects of dapagliflozin,a sodium-glucose co-transporter-2 inhibitor,on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab, 2019,21(2):285-292.
[4]Mansour-Ghanaei F, Pourmasoumi M, Hadi A,et al. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease:A systematic review of randomized controlled trials. Integr Med Res, 2019,8(1):57-61.
[5]Jiang X, Xie L, Huang C,et al. Oral oxymatrine for hepatitis B cirrhosis:A systematic review protocol. Medicine (Baltimore), 2018,97(49):e13482.
[6]An Z, Li J, Yu J,et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. Cell Cycle, 2019,18(21):2928-2938.
[7]Pervez MA, Khan DA, Ijaz A,et al. Effects of delta-tocotrienol supplementation on liver enzymes,inflammation,oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol, 2018,29(2):170-176.
[8]顾立梅,曹培让,顾超,等. 非酒精性脂肪肝中医证型及临床生化指标相关性研究. 南京中医药大学学报,2019,35(6):738-740.
[9]Shen CY, Jiang JG, Yang L,et al. Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine:pharmacological mechanisms and implications for drug discovery. Br J Pharmacol, 2017,174(11):1395-1425.
[10] 王艳,苏峰,李园园,等.蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究.实用肝脏病杂志,2019,22(4):474-477.
[11] Korovljev D, Stajer V, Ostojic J,et al. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease:a randomized controlled pilot trial. Clin Res Hepatol Gastroenterol, 2019,43(6):688-693.
[12] Zhang H, Yang L, Wang Y,et al. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. Life Sci, 2020,257(11):118090.
[13] Zhou L, Wang SB, Chen SG,et al. Prognostic value of ALT,AST,and GGT in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab, 2018,64(10):1739-1747.
[14] Shen Y, Shen X, Cheng Y,et al. Myricitrin pretreatment ameliorates mouse liver ischemia reperfusion injury. Int Immunopharmacol, 2020,89(Pt A):107005.
[15] Shen B, Feng H, Cheng J,et al. Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways. J Cell Mol Med, 2020,24(9):5097-5108.
[16] Jin X, Fu W, Zhou J,et al. Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway. Int J Mol Med, 2021,48(4):187.
[17] 艾正琳,谢步善,姚树坤.苦参碱治疗非酒精性脂肪性肝炎大鼠的效果观察.临床肝胆病杂志,2016,32(11):2163-2166.
[18] Guan B, Chen R, Zhong M,et al. Protective effect of oxymatrine against acute spinal cord injury in rats via modulating oxidative stress,inflammation and apoptosis. Metab Brain Dis,2020,35(1):149-157.
[19] 余小虎,朱金水,顾国妹,等.氧化苦参碱联合二甲双胍对非酒精性脂肪肝患者胰岛素抵抗及血清TNFα的影响. 临床肝胆病杂志,2007,23(3):195-196.
[20] Liu X, Wang D, Yang W,et al. Oxymatrine exerts anti-fibrotic effects in a rat model of hepatic fibrosis by suppressing endoplasmic reticulum stress. J Int Med Res, 2020,48(10):300060520961681.

Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Mi Meng,Lu Bingjiu,Wang Xueliang, et al.. Analysis of blood lipid in patients with metabolism-related fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 653-656.
[2]	Wang Hui, Tang Zhan, Chang Wenjuan, et al.. Comparison of metabolic characteristics and liver steatosis in non-obese and obese patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 669-672.
[3]	Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.
[4]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[5]	Hou Wenjing, Wu Guangming, Gai Huihui. Effect of panax notoginsenosides on liver steatosis and NO/iNOS/NF-κB pathway protein expression in mice with high-fat-induced non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(2): 174-178.
[6]	Liu Shangzhi, Zhang Zhiqiang, Li Shengjin. Protective mechanism of Danzhi Xiaoyao powder on hepatic damage in rats with D-galactosamine/lipopolysaccharides-induced acute liver injury [J]. Journal of Practical Hepatology, 2022, 25(2): 179-182.
[7]	Chen Kai, Ju Feng. Observation of hepatic steatosis score by ultrasonography in patients with nonalcoholic fatty liver diseases after polyene phosphatidylcholineand Fuzheng Huayu capsule combination treatment [J]. Journal of Practical Hepatology, 2022, 25(2): 219-222.
[8]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[9]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[10]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[11]	Shi Xueli, Zhang Wanli, Mao Jun. Serum IL-38 and β2GPI levels in rats with autoimmune hepatitis and their relationship with liver tissue lesions [J]. Journal of Practical Hepatology, 2021, 24(6): 803-806.
[12]	Gu Xuexiang, Li Xiangyu, Shan Qinxing. Protective effect of saikosaponin A on hepatic steatosis in rats with non-alcoholic fatty liver disease by affecting PPARα signaling pathway [J]. Journal of Practical Hepatology, 2021, 24(6): 807-810.
[13]	Ge Haiyan, Kuang Xia, Zhou Ruijun. Changes of serum miR-17, miR-20a and miR-20b levels in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(5): 697-700.
[14]	Xu Xiangtao, Qiao Fei, Che Junyong, et al. Short-term efficacy of Huazhuo Tongyu decoction in the treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(5): 701-704.
[15]	Liu Na, Zhang Huamin, Deng Qiaojuan. Impact of inhibition of TRAF6 gene expression on hepatic NF-κB-related protein expression in rats with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 468-471.